The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material
The registered capital of the newly founded company is € 50 million
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Subscribe To Our Newsletter & Stay Updated
